Coagulation factor x human
Coagadex (coagulation factor x human) is an unknown pharmaceutical. Coagulation factor x human was first approved as Coagadex on 2016-03-16. It has been approved in Europe to treat factor x deficiency.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
367 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 7 | 17 | 7 | 1 | — | 29 |
| Multiple myeloma | D009101 | — | C90.0 | 6 | 12 | 2 | 1 | 1 | 20 |
| Neoplasms | D009369 | — | C80 | 7 | 9 | 4 | 1 | 3 | 20 |
| Plasma cell neoplasms | D054219 | — | — | 4 | 11 | 3 | 1 | 1 | 18 |
| Syndrome | D013577 | — | — | 6 | 8 | 1 | 2 | 4 | 16 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 4 | 5 | 4 | 3 | 3 | 15 |
| Thromboembolism | D013923 | HP_0001907 | — | 1 | 2 | 6 | 1 | 4 | 13 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 6 | 4 | 1 | — | 13 |
| Thrombosis | D013927 | — | — | 1 | — | 4 | 3 | 3 | 11 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | 2 | 3 | 4 | 10 |
Show 41 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 13 | 19 | 13 | — | 4 | 44 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 6 | 12 | 11 | — | 2 | 27 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 14 | 3 | — | 3 | 22 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 13 | 3 | — | 2 | 20 |
| Lymphoid leukemia | D007945 | — | C91 | 5 | 6 | 10 | — | — | 18 |
| Myeloid leukemia | D007951 | — | C92 | 5 | 12 | 3 | — | 1 | 18 |
| Myelodysplastic syndromes | D009190 | — | D46 | 4 | 11 | 1 | — | 2 | 16 |
| Colorectal neoplasms | D015179 | — | — | 4 | 5 | 2 | — | 2 | 10 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 6 | 1 | — | 2 | 10 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 6 | 1 | — | 1 | 9 |
Show 74 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Preleukemia | D011289 | — | — | 3 | 8 | — | — | 1 | 10 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 6 | — | — | 2 | 8 |
| Recurrence | D012008 | — | — | 5 | 3 | — | — | 1 | 7 |
| Adenocarcinoma | D000230 | — | — | 3 | 5 | — | — | 1 | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 4 | — | — | — | 5 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 2 | 2 | — | — | 2 | 5 |
| Carcinoma | D002277 | — | C80.0 | 2 | 3 | — | — | — | 4 |
| Melanoma | D008545 | — | — | 2 | 3 | — | — | — | 4 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 2 | — | — | 1 | 3 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 3 | — | — | — | 3 |
Show 100 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Coagulation protein disorders | D020147 | — | — | 3 | — | — | — | 1 | 4 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | — | — | — | — | 1 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Herb-drug interactions | D041743 | — | — | 1 | — | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | — | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 4 | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 4 | 4 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 4 | 4 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 3 | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 3 | 3 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | — | 3 | 3 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 2 | 2 |
| Risk reduction behavior | D040242 | — | — | — | — | — | — | 2 | 2 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 2 | 2 |
Show 86 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Coagulation factor x human |
| INN | — |
| Description | Factor X, also known by the eponym Stuart–Prower factor, is an enzyme (EC 3.4.21.6) of the coagulation cascade. It is a serine endopeptidase (protease group S1, PA clan). Factor X is synthesized in the liver and requires vitamin K for its synthesis.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297951 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,578 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,513 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use